1672 (1672) News
Follow 1672 (1672) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Ascletis Pharma Inc. Reports Positive 28-Day ASC50 POC Data
Ascletis reported a 48.9% placebo-adjusted PASI reduction after 28 days of once-daily 200 mg ASC50 in mild-to-moderate plaque psoriasis, with a 6.5-day half-life and mild AEs. PASI reduction reached 65.9% 15 days after t
NEWS | Sep 29, 2026, 12:01 AM UTC
L
Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
48.9% placebo-adjusted reduction in psoriasis area and severity index (PASI) score achieved in mild-to-moderate plaque psoriasis patients with once-daily 200 mg 28-day treatment.- Steady-state elimination half-life after
NEWS | Sep 29, 2026, 12:00 AM UTC
M
Ascletis Pharma starts U.S. Phase I study for ASC36 obesity tablets
Ascletis Pharma Inc. has initiated a U.S. Phase I study for ASC36 oral tablets in obesity.
EQUITY | Sep 08, 2026, 10:16 AM UTC
M
Ascletis Pharma shares added to Stock Connect eligible securities
Ascletis Pharma ordinary shares were added to Hong Kong Stock Connect eligible securities, effective Sept. 7.
EQUITY | Sep 07, 2026, 04:38 AM UTC
M
Ascletis Pharma shares included in Hong Kong Stock Connect eligible list
Ascletis Pharma Inc. says its ordinary shares traded on the HK Stock Exchange (HKEX:1672) have been included as eligible securities under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs
EQUITY | Sep 07, 2026, 04:15 AM UTC
L
Ascletis Pharma board does not recommend any dividend for HY
Ascletis Pharma Inc. says its board of directors does not recommend payment of any dividend in respect of HY.
EQUITY | Aug 31, 2026, 04:45 PM UTC
L
Ascletis says first participant dosed in Phase III for ASC30
Ascletis announced the first participant has been dosed in its global Phase III clinical program of once-daily oral small-molecule GLP-1 receptor agonist ASC30 for chronic weight management.
EQUITY | Aug 30, 2026, 10:15 AM UTC